keyboard_arrow_up

Partnering Deals and Alliances with Big Pharma

Reportstack has announced a new market research publication on Partnering Deals and Alliances with Big Pharma which provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
 
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:
 
Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2007, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 
The Partnering Deals and Alliances with Big Pharma report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty big pharma companies.
 
This premier report provides all the information you require to better understand big pharma partnering.
 
One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.
 
Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company’s business development objectives. Over 300 charts allow quick understanding of each big pharma companies dealmaking trends over the last four years.
 
This report contains over 3,000 links to online copies of actual partnering deals as recorded at Current Agreement, together with contract documents if submitted to the Securities Exchange Commission by bigpharma and their partners.
 
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
The report provides an orientation of big pharma’s dealmaking and business activities, an introduction to the report, lists the top 50 leading big pharma companies based on 2012 pharmaceutical revenues and dealmaking activity since 2009, reviews the top partnering and M&A deals of 2009-2014 according to reported deal size.

The report provides a summary on best practice on how to submit an opportunity to big pharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner, lists forthcoming partnering events where valuable face to face meetings with big pharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings. In-depth profiles of every big pharma company provide everything required to assess the suitability of a company as a prospective partner. Each profile includes a company overview, partnering activity according to deal type, phase of development, therapy area and technology type.
 
Each company profile provides a comprehensive listing of deal records available at Current Agreements, each of which links direct to an online copy of the actual deal record plus contract document if filed with the SEC.
 
One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.
 
Understanding the flexibility of a prospective partners’ negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
                                                             
This data driven report contains over 3,000 links to online copies of actual deal records at Current Agreements and contract documents, where submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
 
 In addition, contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal. In summary, the report provides the reader with the tools necessary to make successful contact with the right big pharma partners effectively and efficiently.
 
Key benefits
 
Partnering Deals and Alliances with Big Pharma provides the user with the following key benefits:
 
Detailed partnering activity profiles for each of the top 50 big pharma companies
Over 300 charts showing a company’s dealmaking activity since 2009, allowing quick identification potential partners
Partnering therapy focus revealed
Partnering activity since 2009 – number of deals per year
Full listing of partnering deals
Activity by deal type
Activity by industry sector
Activity by phase of development
Activity by technology type
Activity by therapeutic area
Comprehensive access to over 3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
Insight into the terms included in a partnering agreement, together with real world clause examples, via contract documents
Understand the key deal terms the company has agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
 
Report scope
 
Partnering Deals and Alliances with Big Pharma is intended to provide the reader with an in-depth understanding of the partnering activities of the leading fifty big pharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company’s partnering.
 
Partnering Deals and Alliances with Big Pharma includes:
 
Detailed company profiles for each of the top 50 big pharma companies, including:
Partnering interests and indications
Partnering activity since 2009
Partner companies since 2009
Partnering activity since 2009 by:
Partner company
Deal type
Industry sector
Stage of development
Technology type
Therapy area
Over 300 charts showing the dealmaking activity of each company since 2009
The tools to enable effective and efficient preparation for partnering negotiation with big pharma
3,000 partnering deals as recorded at Current Agreement, together with contract documents if available
The leading M&A and partnering deals by value 2009-2014
 
The Partnering Deals and Alliances with Big Pharma report also provides comprehensive access to available contract documents for each of the fifty big pharma companies.
 
Analyzing actual company agreements allows assessment of the following:
 
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subscontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

To view the table of contents and know more details please visit Partnering Deals and Alliances with Big Pharma report.